4.8 Review

Development and deployment of COVID-19 vaccines for those most vulnerable

Journal

SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 579, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abd1525

Keywords

-

Funding

  1. Human Vaccines Project
  2. NIAID
  3. Canadian Institutes for Health Research Rapid Response Grant for COVID-19
  4. Research Program on Emerging and Re-emerging Infectious Diseases from AMED [19fk0108113]
  5. NIAID [HHSN272201400008C, HHSN272201400006C, 75N93019C00052]
  6. Emory-UGA-CEIRS grant [HHSN272201400004C]
  7. ALSAC
  8. Wellcome Trust
  9. Bharat Biotech

Ask authors/readers for more resources

The development and global deployment of COVID-19 vaccines are crucial in ending the pandemic, but challenges remain in elderly populations and low-resource settings, making distribution and vaccination efforts difficult.
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available